Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

ABACAVIR SULFATE AND LAMIVUDINE

ABACAVIR SULFATE; LAMIVUDINE

Standard Dose
EQ 60MG BASE;30MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview ABACAVIR SULFATE AND LAMIVUDINE is listed in Drugs@FDA under application 204311 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient ABACAVIR SULFATE; LAMIVUDINE Form and strength TABLET, FOR SUSPENSION;ORAL - EQ 60MG BASE;30MG Sponsor PHARMOBEDIENT Submission history Latest submission status date: 2023-12-22 00:00:00.

Structured Monograph

Clinical summary

Approval overview ABACAVIR SULFATE AND LAMIVUDINE is listed in Drugs@FDA under application 204311 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ABACAVIR SULFATE; LAMIVUDINE Form and strength TABLET, FOR SUSPENSION;ORAL - EQ 60MG BASE;30MG Sponsor PHARMOBEDIENT Submission history Latest submission status date: 2023-12-22 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.